A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Children's Oncology Group
Novartis
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Children's Oncology Group
INSYS Therapeutics Inc
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Novartis
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center